The SE Healthcare team has been at the forefront of enhancing safety and quality in healthcare for over 10 years. Our mission is to empower healthcare providers through the Physician Empowerment™ Suite, a set of specialty-specific data analytics platforms created to increase quality of care, reduce risk, improve reputation, and enhance reimbursements to enrich financial health.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIOGEN TO PRESENT AT THE 25TH ANNUAL CREDIT SUISSE HEALTHCARE CONFERENCE

Biogen | October 27, 2016

news image

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 25th Annual Credit Suisse Healthcare Conference. The webcast will be live on Monday, November 7, 2016 at 9:00a.m. MT, 11:00a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation....

Read More

VERTEX TO PRESENT AT THE CREDIT SUISSE HEALTHCARE CONFERENCE ON NOVEMBER 8

Vertex Pharmaceuticals | November 02, 2016

news image

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8th at 3:30 p.m. ET .Management's remarks will be available live through Vertex's website at www.vrtx.com in the "Investors" section under the "Events and Presentations" page. A replay of the conference webcast will be archived on the company's website....

Read More

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

news image

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More

STEM CELL MODELS OF HUMAN SPINE DEVELOPMENT UNVEILED

Drug Target Review | January 15, 2020

news image

Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...

Read More
news image

BIOGEN TO PRESENT AT THE 25TH ANNUAL CREDIT SUISSE HEALTHCARE CONFERENCE

Biogen | October 27, 2016

Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 25th Annual Credit Suisse Healthcare Conference. The webcast will be live on Monday, November 7, 2016 at 9:00a.m. MT, 11:00a.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. An archived version of the webcast will be available for 14 days following the presentation....

Read More
news image

VERTEX TO PRESENT AT THE CREDIT SUISSE HEALTHCARE CONFERENCE ON NOVEMBER 8

Vertex Pharmaceuticals | November 02, 2016

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8th at 3:30 p.m. ET .Management's remarks will be available live through Vertex's website at www.vrtx.com in the "Investors" section under the "Events and Presentations" page. A replay of the conference webcast will be archived on the company's website....

Read More
news image

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More
news image

STEM CELL MODELS OF HUMAN SPINE DEVELOPMENT UNVEILED

Drug Target Review | January 15, 2020

Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...

Read More